Skip to Main Content

Paper Details

Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A.
Clin Adv Hematol Oncol
0
2022
androgen, androgen receptor, nonmetastatic castration-resistant prostate cancer, patients
Author NameAffiliation
William K OhTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Matthew B RettigInstitute of Urologic Oncology, David Geffen School of Medicine at university of california los angeles
Matthew B RettigVA Greater Los Angeles Healthcare System
  • 1 - 3

Datasets

Release 1.2